<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01248949</url>
  </required_header>
  <id_info>
    <org_study_id>CD-ON-MEDI3617-1043</org_study_id>
    <nct_id>NCT01248949</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors</brief_title>
  <official_title>Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the maximum tolerated dose or optimal biological dose, and the safety profile of
      MEDI3617 when given as a single-agent or in combination with other chemotherapeutic agents in
      subjects with advanced solid malignancies resistant to standard therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>From the time of first administration of MEDI3617 single agent or MEDI3617 combination therapy through the first 21-day or 28-day cycle (Cycle 1)</time_frame>
    <description>DLT was defined as any treatment-related, grade 3 or higher toxicity (according to the National Cancer Institute's Common Terminology Criteria for Adverse Events [NCI CTCAE] version 4.0); occurring during the first 21 or 28 days after the initial administration of MEDI3617.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>From the time of first administration of MEDI3617 single agent or MEDI3617 combination therapy through the first 21-day or 28-day cycle (Cycle 1)</time_frame>
    <description>The dose-escalation phase used a 3 + 3 design. If greater than or equal to 2 (≥ 2) participants in a dose cohort experienced a DLT during the DLT period, the MTD was exceeded and no further participants were enrolled into that dose cohort. If this occurred, the preceding dose cohort was evaluated for the MTD and a total of 6 participants were treated at the preceding dose. If less than or equal to 1 (≤ 1) of 6 participants experienced a DLT at the preceding dose, then this dose level was the MTD. DLTs were defined as any treatment-related, grade 3 or higher toxicity (according to the National Cancer Institute's Common Terminology Criteria for Adverse Events [NCI CTCAE] version 4.0); occurring during the first 21 or 28 days after the initial administration of MEDI3617.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)</measure>
    <time_frame>From start of study drug administration up to 90 days after the last dose of MEDI3617</time_frame>
    <description>An adverse event (AE) was any untoward medical occurrence in a participant administered investigational product and which does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) was an AE resulting in any of following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were events occurring after administration of investigational product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Laboratory Abnormalities Recorded as Adverse Events (AEs)</measure>
    <time_frame>From start of study drug administration up to 90 days after the last dose of MEDI3617</time_frame>
    <description>Laboratory evaluations were performed, including hematology and serum chemistry. An AE was any untoward medical occurrence in a participant administered investigational product and which does not necessarily have a causal relationship with this treatment. AEs related to laboratory abnormalities were recorded and reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Vital Sign Abnormalities Recorded as Adverse Events (AEs)</measure>
    <time_frame>From start of study drug administration up to 90 days after the last dose of MEDI3617</time_frame>
    <description>Vital signs included parameters such as heart rate, blood pressure, temperature, weight and respiratory rate. An AE was any untoward medical occurrence in a participant administered investigational product and which does not necessarily have a causal relationship with this treatment. AEs related to vital signs abnormalities were recorded and reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Echocardiogram Abnormalities Recorded as Adverse Events (AEs)</measure>
    <time_frame>From start of study drug administration up to 90 days after the last dose of MEDI3617</time_frame>
    <description>An AE was any untoward medical occurrence in a participant administered investigational product and which does not necessarily have a causal relationship with this treatment. AEs related to echocardiogram abnormalities were recorded and reported. The only AE reported was ejection fraction decreased in the MEDI3617 + Paclitaxel total group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Electrocardiogram Abnormalities Recorded as Adverse Events (AEs)</measure>
    <time_frame>From start of study drug administration up to 90 days after the last dose of MEDI3617</time_frame>
    <description>An AE was any untoward medical occurrence in a participant administered investigational product and which does not necessarily have a causal relationship with this treatment. AEs related to electrocardiogram abnormalities were recorded and reported. The only AE reported was electrocardiogram QT prolonged in the MEDI3617 + Bevacizumab Q2W total group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With a Decline in Karnofsky Performance Status (KPS) of ≥ 20 Points at Worst Record On-study Compared With Baseline</measure>
    <time_frame>From start of study drug administration up to 30 days after the last dose of MEDI3617</time_frame>
    <description>KPS scale: 100 is no evidence of disease; 90 is able to carry on normal activity, minor symptoms of disease; 80 is normal activity with effort, some symptoms of disease; 70 is cares for self; unable to do active work; 60 is requires occasional assistance, but is able to care for most of his needs; 50 is requires considerable assistance with frequent medical care; 40 is disabled, requires special care; 30 is severely disabled, hospitalization is indicated although death is not imminent; 20 is very sick, hospitalization necessary, active support treatment necessary; 10 is moribund, fatal processes progressing rapidly, 0 is dead.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax) of MEDI3617</measure>
    <time_frame>Days 1, 2 (MEDI3617 single agent only), 4, 8, 15 (Cycle 1); Day 1 (Cycle 2 and every cycle after), Day 15 (MEDI3617 + bev Q2W and MEDI3617 + paclitaxel only, Cycle 2 and every cycle after); end of treatment; 30 days and 3 months post last dose</time_frame>
    <description>Cmax is the maximum observed serum concentration of MEDI3617. Here, &quot;n&quot; is number of participants analyzed for this endpoint at a specific dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last) of MEDI3617</measure>
    <time_frame>Days 1, 2 (MEDI3617 single agent only), 4, 8, 15 (Cycle 1); Day 1 (Cycle 2 and every cycle after), Day 15 (MEDI3617 + bev Q2W and MEDI3617 + paclitaxel only, Cycle 2 and every cycle after); end of treatment; 30 days and 3 months post last dose</time_frame>
    <description>AUC0-last is the Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration of MEDI3617. Here, &quot;n&quot; is number of participants analyzed for this endpoint at a specific dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of MEDI3617</measure>
    <time_frame>Days 1, 2 (MEDI3617 single agent only), 4, 8, 15 (Cycle 1); Day 1 (Cycle 2 and every cycle after), Day 15 (MEDI3617 + bev Q2W and MEDI3617 + paclitaxel only, Cycle 2 and every cycle after); end of treatment; 30 days and 3 months post last dose</time_frame>
    <description>The AUC0-inf is the Area Under the Concentration-Time Curve From Time Zero to infinity of MEDI3617. Here, &quot;n&quot; is number of participants analyzed for this endpoint at a specific dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance (CL) of MEDI3617</measure>
    <time_frame>Days 1, 2 (MEDI3617 single agent only), 4, 8, 15 (Cycle 1); Day 1 (Cycle 2 and every cycle after), Day 15 (MEDI3617 + bev Q2W and MEDI3617 + paclitaxel only, Cycle 2 and every cycle after); end of treatment; 30 days and 3 months post last dose</time_frame>
    <description>Systemic clearance describes the removal of drug from a volume of serum in a given unit of time (drug loss from the body). It is measured as milliliter per day (mL/day). Here, &quot;n&quot; is number of participants analyzed for this endpoint at a specific dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half Life (t1/2) of MEDI3617</measure>
    <time_frame>Days 1, 2 (MEDI3617 single agent only), 4, 8, 15 (Cycle 1); Day 1 (Cycle 2 and every cycle after), Day 15 (MEDI3617 + bev Q2W and MEDI3617 + paclitaxel only, Cycle 2 and every cycle after); end of treatment; 30 days and 3 months post last dose</time_frame>
    <description>The t1/2 is the time in days required for the concentration of the drug to reach half of its original value. Here, &quot;n&quot; is number of participants analyzed for this endpoint at a specific dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Positive Anti-Drug Antibody (ADA)</measure>
    <time_frame>Presence of ADA to MEDI3617 were assessed prior to infusion with MEDI3617 on Day 1 of each dosing cycle, as well as the end of treatment, and 30 days, 3 months, and 6 months post last dose of MEDI3617</time_frame>
    <description>The immunogenic potential of MEDI3617 was assessed by summarizing the number and percentage of participants who develop detectable ADA. Immunogenicity assessment included determination of anti-drug (MEDI3617) antibodies in serum samples. Samples were measured for the presence of ADA using validated immunoassays.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Time from the first dose of investigational product until end of study</time_frame>
    <description>Objective response rate defined as the number of participants with confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR was defined as disappearance of all target lesions, any pathological lymph nodes must have reduction in short axis to less than (&lt;) 10 millimeter (the sum may not be &quot;0&quot; if there are target nodes). PR was defined as at least a 30 percent (%) decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>Time from the first dose of investigational product until end of study</time_frame>
    <description>Time to response (TTR) is defined as the time from the study entry to the first documentation of confirmed CR or confirmed PR. CR was defined as disappearance of all target lesions, any pathological lymph nodes must have reduction in short axis to less than (&lt;) 10 millimeter (the sum may not be &quot;0&quot; if there are target nodes). PR was defined as at least a 30 percent (%) decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Analysis was based on responses confirmed at a repeat assessment made at least 4 weeks after the initial response, with the TTR taken as the first time the response was observed, not the confirmation assessment. TTR was evaluated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Time from the first dose of investigational product until end of study</time_frame>
    <description>Duration of response is defined as the duration from the first documentation of objective disease response (ie, confirmed CR or confirmed PR) to the first documented disease progression. The duration of response was censored on the date of last tumor assessment documenting absence of disease progression for participants who have no documented progression prior to data cutoff, dropout, or the initiation of alternate anticancer treatment. Duration of response was evaluated for the subgroup of participants with an objective response using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>Time from the first dose of investigational product until end of study</time_frame>
    <description>Time to progression (TTP) is defined as time from the start of treatment with MEDI3617 until the documentation of disease progression. The TTP was censored on the date of last tumor assessment documenting absence of tumor progression for participants who have no documented progression prior to data cutoff, dropout, or the initiation of alternate anticancer treatment. Participants having no tumor assessments after the start of treatment with MEDI3617 had TTP censored on the first date of treatment with MEDI3617. TTP was evaluated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Time from the first dose of investigational product until end of study</time_frame>
    <description>PFS was measured from the start of treatment with MEDI3617 until the documentation of disease progression or death due to any cause, whichever occurred first. PFS was censored on the date of last tumor assessment documenting absence of tumor progression for participants who have no documented progression and were still alive prior to data cutoff, dropout, or the initiation of alternate anticancer treatment. Participants having no tumor assessments after the start of treatment with MEDI3617 had PFS censored on the first date of treatment with MEDI3617. PFS was evaluated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Time from the first dose of investigational product until death due to any cause</time_frame>
    <description>Overall survival is defined as the time from the start of treatment with MEDI3617 until death. For the participants who were alive at the end of study or lost to follow-up, overall survival was censored on the last date when participants were known to be alive. Overall survival was evaluated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating Levels of Angiopoietin 2 (Ang2)</measure>
    <time_frame>Prior to infusion on Cycle 4 and Cycle 5</time_frame>
    <description>Profile of Ang2 post MEDI3617 administration in relation to time course of antibody concentrations.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">162</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <condition>Advanced Recurrent Ovarian Tumors</condition>
  <arm_group>
    <arm_group_label>MEDI3617 SINGLE AGENT TOTAL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive MEDI3617 via intravenous (IV) infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI3617 + BEVACIZUMAB Q3W ESCALATION</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI3617 + BEVACIZUMAB Q2W TOTAL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI3617 + PACLITAXEL TOTAL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI3617</intervention_name>
    <description>Participants will receive MEDI3617 via IV infusion in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons.</description>
    <arm_group_label>MEDI3617 SINGLE AGENT TOTAL</arm_group_label>
    <arm_group_label>MEDI3617 + BEVACIZUMAB Q3W ESCALATION</arm_group_label>
    <arm_group_label>MEDI3617 + BEVACIZUMAB Q2W TOTAL</arm_group_label>
    <arm_group_label>MEDI3617 + PACLITAXEL TOTAL</arm_group_label>
    <arm_group_label>MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Participants will receive bevacizumab via IV infusion in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons.</description>
    <arm_group_label>MEDI3617 + BEVACIZUMAB Q3W ESCALATION</arm_group_label>
    <arm_group_label>MEDI3617 + BEVACIZUMAB Q2W TOTAL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Participants will receive paclitaxel via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons.</description>
    <arm_group_label>MEDI3617 + PACLITAXEL TOTAL</arm_group_label>
    <arm_group_label>MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Participants will receive carboplatin via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons.</description>
    <arm_group_label>MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with confirmed diagnosis of advanced solid tumors (dose-escalation phase) or
             another solid tumor type based on antitumoral activity (dose-expansion phase) that are
             not responsive to standard therapy or for which no standard therapy exists

          -  Patients must be 18 years of age or older

          -  Karnofsky Performance Status ≥ 70

          -  Toxicities from previous cancer therapies must have recovered to CTCAE Grade = or &lt; 2

          -  Adequate organ and marrow function

          -  Using adequate contraceptive measures, be surgically sterile or post-menopausal

        Exclusion Criteria:

          -  Concurrently enrolled in another clinical study, except for non-interventiona
             observational studies, or if in a follow up period from a previous study

          -  Receipt of any investigational anticancer therapy within 30 days prior to the first
             dose of MEDI3617, or in the case of monoclonal antibodies (eg, bevacizumab), 42 days
             prior to the first dose of MEDI3617

          -  Current or previous treatment with angiopoietin inhibitors, or inhibitors of Tie1 or
             Tie2 including, but not limited to, AMG386, CVX-060, XL880, and XL820

          -  Any concurrent chemotherapy, radiotherapy, immunotherapy, biologic or hormonal therapy
             for cancer treatment

          -  Use of immunosuppressive medication or systemic steroids within 7 days prior to first
             dose of MEDI3617

          -  Any condition that, in the opinion of the investigator, would interfere with
             evaluation of the investigational product or interpretation of subject safety or study
             results

          -  Known bleeding diathesis

          -  Pulmonary hemorrhage or gross hemoptysis within 6 months prior to enrollment

          -  Therapeutic or palliative radiation therapy within 2 weeks prior to enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MedImmune, LLC</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2010</study_first_submitted>
  <study_first_submitted_qc>November 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2010</study_first_posted>
  <results_first_submitted>December 2, 2016</results_first_submitted>
  <results_first_submitted_qc>February 9, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 29, 2017</results_first_posted>
  <last_update_submitted>February 9, 2017</last_update_submitted>
  <last_update_submitted_qc>February 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced solid tumors</keyword>
  <keyword>Advanced recurrent ovarian tumors</keyword>
  <keyword>MEDI3617</keyword>
  <keyword>Ang2</keyword>
  <keyword>Ovarian cancer</keyword>
  <keyword>Malignant glioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 162 participants were screened, of which 46 did not meet eligibility criteria and were considered as screen failures; the remaining 116 participants entered into the study and treated with MEDI3617.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MEDI3617 SINGLE AGENT TOTAL</title>
          <description>Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
        </group>
        <group group_id="P2">
          <title>MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL</title>
          <description>Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
        </group>
        <group group_id="P3">
          <title>MEDI3617 + BEVACIZUMAB Q2W TOTAL</title>
          <description>Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
        </group>
        <group group_id="P4">
          <title>MEDI3617 + PACLITAXEL TOTAL</title>
          <description>Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
        </group>
        <group group_id="P5">
          <title>MEDI3617 + CARBOPLATIN/ PACLITAXEL TOTAL</title>
          <description>Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="38"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="37"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Alternative Therapy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Alternative Therapy.</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Palliative Radiation To Brain Metastases</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entered Hospice And Refused Follow Up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Went To Hospice</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Per Sponsor Request o Discontinue Drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pi Decision Due To Declining Status</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pi Discretion Due To Hospitalisation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lesion In ThoracicSpine Requires Therapy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population included all participants who receive any treatment with MEDI3617.</population>
      <group_list>
        <group group_id="B1">
          <title>MEDI3617 SINGLE AGENT TOTAL</title>
          <description>Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
        </group>
        <group group_id="B2">
          <title>MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL</title>
          <description>Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
        </group>
        <group group_id="B3">
          <title>MEDI3617 + BEVACIZUMAB Q2W TOTAL</title>
          <description>Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
        </group>
        <group group_id="B4">
          <title>MEDI3617 + PACLITAXEL TOTAL</title>
          <description>Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
        </group>
        <group group_id="B5">
          <title>MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL</title>
          <description>Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="38"/>
            <count group_id="B4" value="13"/>
            <count group_id="B5" value="7"/>
            <count group_id="B6" value="116"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.4" spread="12.4"/>
                    <measurement group_id="B2" value="57.4" spread="11.9"/>
                    <measurement group_id="B3" value="57.7" spread="11.2"/>
                    <measurement group_id="B4" value="60.4" spread="12.7"/>
                    <measurement group_id="B5" value="56.7" spread="12.3"/>
                    <measurement group_id="B6" value="59.2" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Dose Limiting Toxicities (DLTs)</title>
        <description>DLT was defined as any treatment-related, grade 3 or higher toxicity (according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events [NCI CTCAE] version 4.0); occurring during the first 21 or 28 days after the initial administration of MEDI3617.</description>
        <time_frame>From the time of first administration of MEDI3617 single agent or MEDI3617 combination therapy through the first 21-day or 28-day cycle (Cycle 1)</time_frame>
        <population>DLT Evaluable population included all participants enrolled in dose-escalation, who received at least 1 full assigned dose of single-agent MEDI3617 or full assigned doses of MEDI3617 and standard therapeutic agents on Cycle 1 and completed safety follow-up or experienced a DLT at any point during the 21-day or 28-day DLT evaluation period.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI3617 SINGLE AGENT TOTAL</title>
            <description>Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
          <group group_id="O2">
            <title>MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL</title>
            <description>Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
          <group group_id="O3">
            <title>MEDI3617 + BEVACIZUMAB Q2W TOTAL</title>
            <description>Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>MEDI3617 + PACLITAXEL TOTAL</title>
            <description>Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL</title>
            <description>Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Dose Limiting Toxicities (DLTs)</title>
          <description>DLT was defined as any treatment-related, grade 3 or higher toxicity (according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events [NCI CTCAE] version 4.0); occurring during the first 21 or 28 days after the initial administration of MEDI3617.</description>
          <population>DLT Evaluable population included all participants enrolled in dose-escalation, who received at least 1 full assigned dose of single-agent MEDI3617 or full assigned doses of MEDI3617 and standard therapeutic agents on Cycle 1 and completed safety follow-up or experienced a DLT at any point during the 21-day or 28-day DLT evaluation period.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (MTD)</title>
        <description>The dose-escalation phase used a 3 + 3 design. If greater than or equal to 2 (≥ 2) participants in a dose cohort experienced a DLT during the DLT period, the MTD was exceeded and no further participants were enrolled into that dose cohort. If this occurred, the preceding dose cohort was evaluated for the MTD and a total of 6 participants were treated at the preceding dose. If less than or equal to 1 (≤ 1) of 6 participants experienced a DLT at the preceding dose, then this dose level was the MTD. DLTs were defined as any treatment-related, grade 3 or higher toxicity (according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events [NCI CTCAE] version 4.0); occurring during the first 21 or 28 days after the initial administration of MEDI3617.</description>
        <time_frame>From the time of first administration of MEDI3617 single agent or MEDI3617 combination therapy through the first 21-day or 28-day cycle (Cycle 1)</time_frame>
        <population>DLT Evaluable population included all participants enrolled in dose-escalation, who received at least 1 full assigned dose of single-agent MEDI3617 or full assigned doses of MEDI3617 and standard therapeutic agents on Cycle 1 and completed safety follow-up or experienced a DLT at any point during the 21-day or 28-day DLT evaluation period.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI3617 SINGLE AGENT TOTAL</title>
            <description>Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
          <group group_id="O2">
            <title>MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL</title>
            <description>Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
          <group group_id="O3">
            <title>MEDI3617 + BEVACIZUMAB Q2W TOTAL</title>
            <description>Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>MEDI3617 + PACLITAXEL TOTAL</title>
            <description>Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL</title>
            <description>Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose (MTD)</title>
          <description>The dose-escalation phase used a 3 + 3 design. If greater than or equal to 2 (≥ 2) participants in a dose cohort experienced a DLT during the DLT period, the MTD was exceeded and no further participants were enrolled into that dose cohort. If this occurred, the preceding dose cohort was evaluated for the MTD and a total of 6 participants were treated at the preceding dose. If less than or equal to 1 (≤ 1) of 6 participants experienced a DLT at the preceding dose, then this dose level was the MTD. DLTs were defined as any treatment-related, grade 3 or higher toxicity (according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events [NCI CTCAE] version 4.0); occurring during the first 21 or 28 days after the initial administration of MEDI3617.</description>
          <population>DLT Evaluable population included all participants enrolled in dose-escalation, who received at least 1 full assigned dose of single-agent MEDI3617 or full assigned doses of MEDI3617 and standard therapeutic agents on Cycle 1 and completed safety follow-up or experienced a DLT at any point during the 21-day or 28-day DLT evaluation period.</population>
          <units>milligram (mg)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The highest dose level was cleared and the MTD was not reached.</measurement>
                    <measurement group_id="O2" value="NA">A DLT was reported at the highest dose level, but only 5 out of the 6 participants enrolled were evaluable for DLT. Thus, it is unclear if the MTD was exceeded or reached at the highest dose level tested.</measurement>
                    <measurement group_id="O3" value="NA">The highest dose level was cleared and the MTD was not reached.</measurement>
                    <measurement group_id="O4" value="NA">The highest dose level was cleared and the MTD was not reached.</measurement>
                    <measurement group_id="O5" value="NA">A DLT was reported at the highest dose level, but it is unclear if the MTD was exceeded or reached, as only 3 participants were enrolled (all participants were evaluable for DLT).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)</title>
        <description>An adverse event (AE) was any untoward medical occurrence in a participant administered investigational product and which does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) was an AE resulting in any of following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were events occurring after administration of investigational product.</description>
        <time_frame>From start of study drug administration up to 90 days after the last dose of MEDI3617</time_frame>
        <population>Safety population included all participants who received treatment with MEDI3617.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI3617 SINGLE AGENT TOTAL</title>
            <description>Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
          <group group_id="O2">
            <title>MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL</title>
            <description>Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
          <group group_id="O3">
            <title>MEDI3617 + BEVACIZUMAB Q2W TOTAL</title>
            <description>Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>MEDI3617 + PACLITAXEL TOTAL</title>
            <description>Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL</title>
            <description>Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)</title>
          <description>An adverse event (AE) was any untoward medical occurrence in a participant administered investigational product and which does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) was an AE resulting in any of following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were events occurring after administration of investigational product.</description>
          <population>Safety population included all participants who received treatment with MEDI3617.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TESAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Laboratory Abnormalities Recorded as Adverse Events (AEs)</title>
        <description>Laboratory evaluations were performed, including hematology and serum chemistry. An AE was any untoward medical occurrence in a participant administered investigational product and which does not necessarily have a causal relationship with this treatment. AEs related to laboratory abnormalities were recorded and reported.</description>
        <time_frame>From start of study drug administration up to 90 days after the last dose of MEDI3617</time_frame>
        <population>Safety population included all participants who received treatment with MEDI3617.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI3617 SINGLE AGENT TOTAL</title>
            <description>Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
          <group group_id="O2">
            <title>MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL</title>
            <description>Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
          <group group_id="O3">
            <title>MEDI3617 + BEVACIZUMAB Q2W TOTAL</title>
            <description>Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>MEDI3617 + PACLITAXEL TOTAL</title>
            <description>Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL</title>
            <description>Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Laboratory Abnormalities Recorded as Adverse Events (AEs)</title>
          <description>Laboratory evaluations were performed, including hematology and serum chemistry. An AE was any untoward medical occurrence in a participant administered investigational product and which does not necessarily have a causal relationship with this treatment. AEs related to laboratory abnormalities were recorded and reported.</description>
          <population>Safety population included all participants who received treatment with MEDI3617.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematology: Anemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematology: Leukopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematology: Neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematology: Thombocytopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematology: White blood cell count decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SerChem: Alanine aminotransferase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SerChem: Aspartate aminotransferase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SerChem: Blood alkaline phosphatase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SerChem: Blood creatinine increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SerChem: Blood lactate dehydrogenase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SerChem: Blood potassium increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SerChem: Blood triglycerides increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SerChem: Blood urea increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SerChem: Gamma-glutamyltransferase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SerChem: Hyperglycaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SerChem: Hyperkalaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SerChem: Hypertriglyceridaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SerChem: Hyperuricaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SerChem: Hypoalbuminaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SerChem: Hypocalcaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SerChem: Hypoglycaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SerChem: Hypokalaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SerChem: Hypomagnesaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SerChem: Hyponatremia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Vital Sign Abnormalities Recorded as Adverse Events (AEs)</title>
        <description>Vital signs included parameters such as heart rate, blood pressure, temperature, weight and respiratory rate. An AE was any untoward medical occurrence in a participant administered investigational product and which does not necessarily have a causal relationship with this treatment. AEs related to vital signs abnormalities were recorded and reported.</description>
        <time_frame>From start of study drug administration up to 90 days after the last dose of MEDI3617</time_frame>
        <population>Safety population included all participants who received treatment with MEDI3617.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI3617 SINGLE AGENT TOTAL</title>
            <description>Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
          <group group_id="O2">
            <title>MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL</title>
            <description>Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
          <group group_id="O3">
            <title>MEDI3617 + BEVACIZUMAB Q2W TOTAL</title>
            <description>Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>MEDI3617 + PACLITAXEL TOTAL</title>
            <description>Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL</title>
            <description>Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vital Sign Abnormalities Recorded as Adverse Events (AEs)</title>
          <description>Vital signs included parameters such as heart rate, blood pressure, temperature, weight and respiratory rate. An AE was any untoward medical occurrence in a participant administered investigational product and which does not necessarily have a causal relationship with this treatment. AEs related to vital signs abnormalities were recorded and reported.</description>
          <population>Safety population included all participants who received treatment with MEDI3617.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Arrhythmia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sinus tachycardia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tachycardia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pyrexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypotension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Echocardiogram Abnormalities Recorded as Adverse Events (AEs)</title>
        <description>An AE was any untoward medical occurrence in a participant administered investigational product and which does not necessarily have a causal relationship with this treatment. AEs related to echocardiogram abnormalities were recorded and reported. The only AE reported was ejection fraction decreased in the MEDI3617 + Paclitaxel total group.</description>
        <time_frame>From start of study drug administration up to 90 days after the last dose of MEDI3617</time_frame>
        <population>Safety population included all participants who received treatment with MEDI3617.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI3617 SINGLE AGENT TOTAL</title>
            <description>Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
          <group group_id="O2">
            <title>MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL</title>
            <description>Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
          <group group_id="O3">
            <title>MEDI3617 + BEVACIZUMAB Q2W TOTAL</title>
            <description>Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>MEDI3617 + PACLITAXEL TOTAL</title>
            <description>Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL</title>
            <description>Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Echocardiogram Abnormalities Recorded as Adverse Events (AEs)</title>
          <description>An AE was any untoward medical occurrence in a participant administered investigational product and which does not necessarily have a causal relationship with this treatment. AEs related to echocardiogram abnormalities were recorded and reported. The only AE reported was ejection fraction decreased in the MEDI3617 + Paclitaxel total group.</description>
          <population>Safety population included all participants who received treatment with MEDI3617.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Electrocardiogram Abnormalities Recorded as Adverse Events (AEs)</title>
        <description>An AE was any untoward medical occurrence in a participant administered investigational product and which does not necessarily have a causal relationship with this treatment. AEs related to electrocardiogram abnormalities were recorded and reported. The only AE reported was electrocardiogram QT prolonged in the MEDI3617 + Bevacizumab Q2W total group.</description>
        <time_frame>From start of study drug administration up to 90 days after the last dose of MEDI3617</time_frame>
        <population>Safety population included all participants who received treatment with MEDI3617</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI3617 SINGLE AGENT TOTAL</title>
            <description>Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
          <group group_id="O2">
            <title>MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL</title>
            <description>Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
          <group group_id="O3">
            <title>MEDI3617 + BEVACIZUMAB Q2W TOTAL</title>
            <description>Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>MEDI3617 + PACLITAXEL TOTAL</title>
            <description>Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL</title>
            <description>Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Electrocardiogram Abnormalities Recorded as Adverse Events (AEs)</title>
          <description>An AE was any untoward medical occurrence in a participant administered investigational product and which does not necessarily have a causal relationship with this treatment. AEs related to electrocardiogram abnormalities were recorded and reported. The only AE reported was electrocardiogram QT prolonged in the MEDI3617 + Bevacizumab Q2W total group.</description>
          <population>Safety population included all participants who received treatment with MEDI3617</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Serum Concentration (Cmax) of MEDI3617</title>
        <description>Cmax is the maximum observed serum concentration of MEDI3617. Here, &quot;n&quot; is number of participants analyzed for this endpoint at a specific dose.</description>
        <time_frame>Days 1, 2 (MEDI3617 single agent only), 4, 8, 15 (Cycle 1); Day 1 (Cycle 2 and every cycle after), Day 15 (MEDI3617 + bev Q2W and MEDI3617 + paclitaxel only, Cycle 2 and every cycle after); end of treatment; 30 days and 3 months post last dose</time_frame>
        <population>All participants who received treatment with MEDI3617 and for whom PK blood samples were collected and evaluated.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI3617 SINGLE AGENT TOTAL</title>
            <description>Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
          <group group_id="O2">
            <title>MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL</title>
            <description>Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
          <group group_id="O3">
            <title>MEDI3617 + BEVACIZUMAB Q2W TOTAL</title>
            <description>Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>MEDI3617 + PACLITAXEL TOTAL</title>
            <description>Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL</title>
            <description>Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Serum Concentration (Cmax) of MEDI3617</title>
          <description>Cmax is the maximum observed serum concentration of MEDI3617. Here, &quot;n&quot; is number of participants analyzed for this endpoint at a specific dose.</description>
          <population>All participants who received treatment with MEDI3617 and for whom PK blood samples were collected and evaluated.</population>
          <units>microgram per milliliter (mcg/ml)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cohort -2 (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.39" spread="0.254"/>
                    <measurement group_id="O2" value="NA">Cohort -2 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort -2 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort -2 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort -2 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort -1 (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.44">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O2" value="NA">Cohort -1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort -1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort -1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort -1 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort 1 (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.63" spread="3.48"/>
                    <measurement group_id="O2" value="NA">Cohort 1 was part of the MEDI3617 Single agent total group</measurement>
                    <measurement group_id="O3" value="NA">Cohort 1 was part of the MEDI3617 Single agent total group</measurement>
                    <measurement group_id="O4" value="NA">Cohort 1 was part of the MEDI3617 Single agent total group</measurement>
                    <measurement group_id="O5" value="NA">Cohort 1 was part of the MEDI3617 Single agent total group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort 2 (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.2" spread="28.8"/>
                    <measurement group_id="O2" value="NA">Cohort 2 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort 2 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort 2 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort 2 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort 3 (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.4" spread="2.68"/>
                    <measurement group_id="O2" value="NA">Cohort 3 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort 3 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort 3 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort 3 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort 4 (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="239" spread="79.5"/>
                    <measurement group_id="O2" value="NA">Cohort 4 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort 4 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort 4 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort 4 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort 5 (n=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="785" spread="189"/>
                    <measurement group_id="O2" value="NA">Cohort 5 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort 5 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort 5 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort 5 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort ovarian cancer expansion (OCE) -1 (n=15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="336" spread="62.2"/>
                    <measurement group_id="O2" value="NA">Cohort OCE -1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort OCE -1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort OCE -1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort OCE -1 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort OCE 1 (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="346">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O2" value="NA">Cohort OCE 1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort OCE 1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort OCE 1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort OCE 1 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MB 1A (n=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O2" value="30.4" spread="26.8"/>
                    <measurement group_id="O3" value="NA">Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MB 2A (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O2" value="55.3" spread="12.6"/>
                    <measurement group_id="O3" value="NA">Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MB 3A (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O2" value="235" spread="90.5"/>
                    <measurement group_id="O3" value="NA">Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MB 4A (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O2" value="348" spread="54.6"/>
                    <measurement group_id="O3" value="NA">Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MB 1B (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O3" value="44.5" spread="39.3"/>
                    <measurement group_id="O4" value="NA">Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MB 2B (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O3" value="47.5" spread="23.3"/>
                    <measurement group_id="O4" value="NA">Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MB 3B (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O3" value="116" spread="35.1"/>
                    <measurement group_id="O4" value="NA">Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MB 4B (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O3" value="275" spread="86.2"/>
                    <measurement group_id="O4" value="NA">Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort TT2A (n=9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort TT2A (participants with bevacizumab-refractory glioma), was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort TT2A (participants with bevacizumab-refractory glioma), was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O3" value="320" spread="170"/>
                    <measurement group_id="O4" value="NA">Cohort TT2A (participants with bevacizumab-refractory glioma), was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort TT2A (participants with bevacizumab-refractory glioma), was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MP1 (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MP1 was part of the MEDI3617 + Paclitaxel group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MP1 was part of the MEDI3617 + Paclitaxel group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort MP1 was part of the MEDI3617 + Paclitaxel group.</measurement>
                    <measurement group_id="O4" value="114" spread="22.5"/>
                    <measurement group_id="O5" value="NA">Cohort MP1 was part of the MEDI3617 + Paclitaxel group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MP2 (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MP2 was part of the MEDI3617 + Paclitaxel group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MP2 was part of the MEDI3617 + Paclitaxel group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort MP2 was part of the MEDI3617 + Paclitaxel group.</measurement>
                    <measurement group_id="O4" value="209" spread="57.4"/>
                    <measurement group_id="O5" value="NA">Cohort MP2 was part of the MEDI3617 + Paclitaxel group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MCP1 (n=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O5" value="200" spread="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MCP2 (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MCP2 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MCP2 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort MCP2 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort MCP2 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O5" value="585" spread="491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last) of MEDI3617</title>
        <description>AUC0-last is the Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration of MEDI3617. Here, &quot;n&quot; is number of participants analyzed for this endpoint at a specific dose.</description>
        <time_frame>Days 1, 2 (MEDI3617 single agent only), 4, 8, 15 (Cycle 1); Day 1 (Cycle 2 and every cycle after), Day 15 (MEDI3617 + bev Q2W and MEDI3617 + paclitaxel only, Cycle 2 and every cycle after); end of treatment; 30 days and 3 months post last dose</time_frame>
        <population>All participants who received treatment with MEDI3617 and for whom PK blood samples were collected and evaluated.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI3617 SINGLE AGENT TOTAL</title>
            <description>Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
          <group group_id="O2">
            <title>MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL</title>
            <description>Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
          <group group_id="O3">
            <title>MEDI3617 + BEVACIZUMAB Q2W TOTAL</title>
            <description>Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>MEDI3617 + PACLITAXEL TOTAL</title>
            <description>Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL</title>
            <description>Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last) of MEDI3617</title>
          <description>AUC0-last is the Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration of MEDI3617. Here, &quot;n&quot; is number of participants analyzed for this endpoint at a specific dose.</description>
          <population>All participants who received treatment with MEDI3617 and for whom PK blood samples were collected and evaluated.</population>
          <units>day*mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cohort -2 (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.429"/>
                    <measurement group_id="O2" value="NA">Cohort -2 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort -2 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort -2 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort -2 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort -1 (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O2" value="NA">Cohort -1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort -1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort -1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort -1 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort 1 (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" spread="11.8"/>
                    <measurement group_id="O2" value="NA">Cohort 1 was part of the MEDI3617 Single agent total group</measurement>
                    <measurement group_id="O3" value="NA">Cohort 1 was part of the MEDI3617 Single agent total group</measurement>
                    <measurement group_id="O4" value="NA">Cohort 1 was part of the MEDI3617 Single agent total group</measurement>
                    <measurement group_id="O5" value="NA">Cohort 1 was part of the MEDI3617 Single agent total group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort 2 (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171" spread="69"/>
                    <measurement group_id="O2" value="NA">Cohort 2 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort 2 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort 2 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort 2 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort 3 (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="438" spread="204"/>
                    <measurement group_id="O2" value="NA">Cohort 3 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort 3 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort 3 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort 3 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort 4 (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2610" spread="1570"/>
                    <measurement group_id="O2" value="NA">Cohort 4 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort 4 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort 4 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort 4 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort 5 (n=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3650" spread="2600"/>
                    <measurement group_id="O2" value="NA">Cohort 5 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort 5 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort 5 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort 5 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort OCE -1 (n=15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2610" spread="891"/>
                    <measurement group_id="O2" value="NA">Cohort OCE -1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort OCE -1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort OCE -1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort OCE -1 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort OCE 1 (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2160">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O2" value="NA">Cohort OCE 1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort OCE 1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort OCE 1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort OCE 1 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MB 1A (n=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O2" value="101" spread="48.8"/>
                    <measurement group_id="O3" value="NA">Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MB 2A (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O2" value="473" spread="223"/>
                    <measurement group_id="O3" value="NA">Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MB 3A (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O2" value="2280" spread="529"/>
                    <measurement group_id="O3" value="NA">Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MB 4A (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O2" value="2710" spread="1070"/>
                    <measurement group_id="O3" value="NA">Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MB 1B (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O3" value="94.7" spread="48.7"/>
                    <measurement group_id="O4" value="NA">Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MB 2B (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O3" value="216" spread="61.8"/>
                    <measurement group_id="O4" value="NA">Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MB 3B (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O3" value="805" spread="292"/>
                    <measurement group_id="O4" value="NA">Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MB 4B (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O3" value="2310" spread="941"/>
                    <measurement group_id="O4" value="NA">Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort TT2A (n=9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort TT2A (participants with bevacizumab-refractory glioma), was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort TT2A (participants with bevacizumab-refractory glioma), was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O3" value="2590" spread="1920"/>
                    <measurement group_id="O4" value="NA">Cohort TT2A (participants with bevacizumab-refractory glioma), was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort TT2A (participants with bevacizumab-refractory glioma), was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MP1 (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MP1 was part of the MEDI3617 + Paclitaxel group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MP1 was part of the MEDI3617 + Paclitaxel group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort MP1 was part of the MEDI3617 + Paclitaxel group.</measurement>
                    <measurement group_id="O4" value="551" spread="331"/>
                    <measurement group_id="O5" value="NA">Cohort MP1 was part of the MEDI3617 + Paclitaxel group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MP2 (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MP2 was part of the MEDI3617 + Paclitaxel group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MP2 was part of the MEDI3617 + Paclitaxel group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort MP2 was part of the MEDI3617 + Paclitaxel group.</measurement>
                    <measurement group_id="O4" value="1460" spread="484"/>
                    <measurement group_id="O5" value="NA">Cohort MP2 was part of the MEDI3617 + Paclitaxel group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MCP1 (n=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O5" value="1240" spread="882"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MCP2 (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MCP2 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MCP2 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort MCP2 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort MCP2 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O5" value="2890" spread="257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of MEDI3617</title>
        <description>The AUC0-inf is the Area Under the Concentration-Time Curve From Time Zero to infinity of MEDI3617. Here, &quot;n&quot; is number of participants analyzed for this endpoint at a specific dose.</description>
        <time_frame>Days 1, 2 (MEDI3617 single agent only), 4, 8, 15 (Cycle 1); Day 1 (Cycle 2 and every cycle after), Day 15 (MEDI3617 + bev Q2W and MEDI3617 + paclitaxel only, Cycle 2 and every cycle after); end of treatment; 30 days and 3 months post last dose</time_frame>
        <population>All participants who received treatment with MEDI3617 and for whom PK blood samples were collected and evaluated.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI3617 SINGLE AGENT TOTAL</title>
            <description>Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
          <group group_id="O2">
            <title>MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL</title>
            <description>Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
          <group group_id="O3">
            <title>MEDI3617 + BEVACIZUMAB Q2W TOTAL</title>
            <description>Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>MEDI3617 + PACLITAXEL TOTAL</title>
            <description>Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL</title>
            <description>Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of MEDI3617</title>
          <description>The AUC0-inf is the Area Under the Concentration-Time Curve From Time Zero to infinity of MEDI3617. Here, &quot;n&quot; is number of participants analyzed for this endpoint at a specific dose.</description>
          <population>All participants who received treatment with MEDI3617 and for whom PK blood samples were collected and evaluated.</population>
          <units>day*mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cohort -2 (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.79">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O2" value="NA">Cohort -2 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort -2 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort -2 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort -2 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort 1 (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.12">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O2" value="NA">Cohort 1 was part of the MEDI3617 Single agent total group</measurement>
                    <measurement group_id="O3" value="NA">Cohort 1 was part of the MEDI3617 Single agent total group</measurement>
                    <measurement group_id="O4" value="NA">Cohort 1 was part of the MEDI3617 Single agent total group</measurement>
                    <measurement group_id="O5" value="NA">Cohort 1 was part of the MEDI3617 Single agent total group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort 2 (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="269">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O2" value="NA">Cohort 2 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort 2 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort 2 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort 2 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort 3 (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="529" spread="269"/>
                    <measurement group_id="O2" value="NA">Cohort 3 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort 3 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort 3 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort 3 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort 4 (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2150">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O2" value="NA">Cohort 4 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort 4 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort 4 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort 4 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort 5 (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4230">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O2" value="NA">Cohort 5 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort 5 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort 5 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort 5 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort OCE -1 (n=12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3280" spread="1410"/>
                    <measurement group_id="O2" value="NA">Cohort OCE -1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort OCE -1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort OCE -1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort OCE -1 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort OCE 1 (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2490">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O2" value="NA">Cohort OCE 1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort OCE 1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort OCE 1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort OCE 1 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MB 1A (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O2" value="110" spread="58.1"/>
                    <measurement group_id="O3" value="NA">Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MB 2A (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O2" value="628" spread="376"/>
                    <measurement group_id="O3" value="NA">Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MB 4A (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O2" value="3920">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O3" value="NA">Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MB 1B (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O3" value="104" spread="61"/>
                    <measurement group_id="O4" value="NA">Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MB 2B (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O3" value="252" spread="83.2"/>
                    <measurement group_id="O4" value="NA">Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MB 3B (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O3" value="1200">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O4" value="NA">Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MB 4B (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O3" value="4630">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O4" value="NA">Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MP1 (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MP1 was part of the MEDI3617 + Paclitaxel group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MP1 was part of the MEDI3617 + Paclitaxel group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort MP1 was part of the MEDI3617 + Paclitaxel group.</measurement>
                    <measurement group_id="O4" value="849" spread="163"/>
                    <measurement group_id="O5" value="NA">Cohort MP1 was part of the MEDI3617 + Paclitaxel group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MP2 (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MP2 was part of the MEDI3617 + Paclitaxel group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MP2 was part of the MEDI3617 + Paclitaxel group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort MP2 was part of the MEDI3617 + Paclitaxel group.</measurement>
                    <measurement group_id="O4" value="2810">Cohort MP2 was part of the MEDI3617 + Paclitaxel group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MP2 was part of the MEDI3617 + Paclitaxel group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MCP1 (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O5" value="2240">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MCP2 (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MCP2 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MCP2 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort MCP2 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort MCP2 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O5" value="3560">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systemic Clearance (CL) of MEDI3617</title>
        <description>Systemic clearance describes the removal of drug from a volume of serum in a given unit of time (drug loss from the body). It is measured as milliliter per day (mL/day). Here, &quot;n&quot; is number of participants analyzed for this endpoint at a specific dose.</description>
        <time_frame>Days 1, 2 (MEDI3617 single agent only), 4, 8, 15 (Cycle 1); Day 1 (Cycle 2 and every cycle after), Day 15 (MEDI3617 + bev Q2W and MEDI3617 + paclitaxel only, Cycle 2 and every cycle after); end of treatment; 30 days and 3 months post last dose</time_frame>
        <population>All participants who received treatment with MEDI3617 and for whom PK blood samples were collected and evaluated.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI3617 SINGLE AGENT TOTAL</title>
            <description>Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
          <group group_id="O2">
            <title>MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL</title>
            <description>Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
          <group group_id="O3">
            <title>MEDI3617 + BEVACIZUMAB Q2W TOTAL</title>
            <description>Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>MEDI3617 + PACLITAXEL TOTAL</title>
            <description>Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL</title>
            <description>Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Systemic Clearance (CL) of MEDI3617</title>
          <description>Systemic clearance describes the removal of drug from a volume of serum in a given unit of time (drug loss from the body). It is measured as milliliter per day (mL/day). Here, &quot;n&quot; is number of participants analyzed for this endpoint at a specific dose.</description>
          <population>All participants who received treatment with MEDI3617 and for whom PK blood samples were collected and evaluated.</population>
          <units>milliliter per day (mL/day)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cohort -2 (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2790">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O2" value="NA">Cohort -2 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort -2 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort -2 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort -2 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort 1 (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2460">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O2" value="NA">Cohort 1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort 1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort 1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort 1 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort 2 (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="423">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O2" value="NA">Cohort 2 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort 2 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort 2 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort 2 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort 3 (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="679" spread="345"/>
                    <measurement group_id="O2" value="NA">Cohort 3 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort 3 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort 3 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort 3 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort 4 (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="465">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O2" value="NA">Cohort 4 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort 4 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort 4 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort 4 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort 5 (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="355">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O2" value="NA">Cohort 5 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort 5 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort 5 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort 5 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort OCE -1 (n=12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="352" spread="136"/>
                    <measurement group_id="O2" value="NA">Cohort OCE -1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort OCE -1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort OCE -1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort OCE -1 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort OCE 1 (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="603">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O2" value="NA">Cohort OCE 1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort OCE 1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort OCE 1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort OCE 1 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MB 1A (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O2" value="1060" spread="426"/>
                    <measurement group_id="O3" value="NA">Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MB 2A (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O2" value="614" spread="363"/>
                    <measurement group_id="O3" value="NA">Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MB 4A (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O2" value="388">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O3" value="NA">Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MB 1B (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O3" value="797" spread="499"/>
                    <measurement group_id="O4" value="NA">Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MB 2B (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O3" value="847" spread="237"/>
                    <measurement group_id="O4" value="NA">Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MB 3B(n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O3" value="501">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O4" value="NA">Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MB 4B (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O3" value="216">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O4" value="NA">Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MP1 (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MP1 was part of the MEDI3617 + Paclitaxel group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MP1 was part of the MEDI3617 + Paclitaxel group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort MP1 was part of the MEDI3617 + Paclitaxel group.</measurement>
                    <measurement group_id="O4" value="727" spread="157"/>
                    <measurement group_id="O5" value="NA">Cohort MP1 was part of the MEDI3617 + Paclitaxel group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MP2 (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MP2 was part of the MEDI3617 + Paclitaxel group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MP2 was part of the MEDI3617 + Paclitaxel group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort MP2 was part of the MEDI3617 + Paclitaxel group.</measurement>
                    <measurement group_id="O4" value="356">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O5" value="NA">Cohort MP2 was part of the MEDI3617 + Paclitaxel group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MCP1 (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O5" value="446">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MCP2 (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MCP2 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MCP2 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort MCP2 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort MCP2 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O5" value="424">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Half Life (t1/2) of MEDI3617</title>
        <description>The t1/2 is the time in days required for the concentration of the drug to reach half of its original value. Here, &quot;n&quot; is number of participants analyzed for this endpoint at a specific dose.</description>
        <time_frame>Days 1, 2 (MEDI3617 single agent only), 4, 8, 15 (Cycle 1); Day 1 (Cycle 2 and every cycle after), Day 15 (MEDI3617 + bev Q2W and MEDI3617 + paclitaxel only, Cycle 2 and every cycle after); end of treatment; 30 days and 3 months post last dose</time_frame>
        <population>All participants who received treatment with MEDI3617 and for whom PK blood samples were collected and evaluated.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI3617 SINGLE AGENT TOTAL</title>
            <description>Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
          <group group_id="O2">
            <title>MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL</title>
            <description>Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
          <group group_id="O3">
            <title>MEDI3617 + BEVACIZUMAB Q2W TOTAL</title>
            <description>Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>MEDI3617 + PACLITAXEL TOTAL</title>
            <description>Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL</title>
            <description>Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half Life (t1/2) of MEDI3617</title>
          <description>The t1/2 is the time in days required for the concentration of the drug to reach half of its original value. Here, &quot;n&quot; is number of participants analyzed for this endpoint at a specific dose.</description>
          <population>All participants who received treatment with MEDI3617 and for whom PK blood samples were collected and evaluated.</population>
          <units>day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cohort -2 (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.585">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O2" value="NA">Cohort -2 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort -2 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort -2 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort -2 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort 1 (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.26">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O2" value="NA">Cohort 1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort 1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort 1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort 1 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort 2 (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.86">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O2" value="NA">Cohort 2 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort 2 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort 2 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort 2 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort 3 (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.98" spread="3.09"/>
                    <measurement group_id="O2" value="NA">Cohort 3 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort 3 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort 3 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort 3 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort 4 (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.68">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O2" value="NA">Cohort 4 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort 4 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort 4 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort 4 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort 5 (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.79">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O2" value="NA">Cohort 5 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort 5 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort 5 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort 5 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort OCE -1 (n=12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" spread="3.15"/>
                    <measurement group_id="O2" value="NA">Cohort OCE -1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort OCE -1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort OCE -1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort OCE -1 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort OCE 1 (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.03">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O2" value="NA">Cohort OCE 1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort OCE 1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort OCE 1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort OCE 1 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MB 1A (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O2" value="3.59" spread="0.983"/>
                    <measurement group_id="O3" value="NA">Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MB 2A (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O2" value="9.67" spread="3.35"/>
                    <measurement group_id="O3" value="NA">Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MB 4A (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O2" value="12.3">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O3" value="NA">Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MB 1B (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O3" value="3.9" spread="2.69"/>
                    <measurement group_id="O4" value="NA">Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MB 2B (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O3" value="5.12" spread="0.541"/>
                    <measurement group_id="O4" value="NA">Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MB 3B(n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O3" value="8.23">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O4" value="NA">Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MB 4B (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O3" value="10.2">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O4" value="NA">Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MP1 (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MP1 was part of the MEDI3617 + Paclitaxel group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MP1 was part of the MEDI3617 + Paclitaxel group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort MP1 was part of the MEDI3617 + Paclitaxel group.</measurement>
                    <measurement group_id="O4" value="6.96" spread="1.59"/>
                    <measurement group_id="O5" value="NA">Cohort MP1 was part of the MEDI3617 + Paclitaxel group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MP2 (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MP2 was part of the MEDI3617 + Paclitaxel group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MP2 was part of the MEDI3617 + Paclitaxel group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort MP2 was part of the MEDI3617 + Paclitaxel group.</measurement>
                    <measurement group_id="O4" value="9.34">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O5" value="NA">Cohort MP2 was part of the MEDI3617 + Paclitaxel group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MCP1 (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O5" value="15.1">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort MCP2 (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MCP2 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MCP2 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort MCP2 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort MCP2 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O5" value="11.1">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Positive Anti-Drug Antibody (ADA)</title>
        <description>The immunogenic potential of MEDI3617 was assessed by summarizing the number and percentage of participants who develop detectable ADA. Immunogenicity assessment included determination of anti-drug (MEDI3617) antibodies in serum samples. Samples were measured for the presence of ADA using validated immunoassays.</description>
        <time_frame>Presence of ADA to MEDI3617 were assessed prior to infusion with MEDI3617 on Day 1 of each dosing cycle, as well as the end of treatment, and 30 days, 3 months, and 6 months post last dose of MEDI3617</time_frame>
        <population>All participants who received treatment with MEDI3617.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI3617 SINGLE AGENT TOTAL</title>
            <description>Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
          <group group_id="O2">
            <title>MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL</title>
            <description>Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
          <group group_id="O3">
            <title>MEDI3617 + BEVACIZUMAB Q2W TOTAL</title>
            <description>Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>MEDI3617 + PACLITAXEL TOTAL</title>
            <description>Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL</title>
            <description>Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Positive Anti-Drug Antibody (ADA)</title>
          <description>The immunogenic potential of MEDI3617 was assessed by summarizing the number and percentage of participants who develop detectable ADA. Immunogenicity assessment included determination of anti-drug (MEDI3617) antibodies in serum samples. Samples were measured for the presence of ADA using validated immunoassays.</description>
          <population>All participants who received treatment with MEDI3617.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate (ORR)</title>
        <description>Objective response rate defined as the number of participants with confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR was defined as disappearance of all target lesions, any pathological lymph nodes must have reduction in short axis to less than (&lt;) 10 millimeter (the sum may not be “0” if there are target nodes). PR was defined as at least a 30 percent (%) decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.</description>
        <time_frame>Time from the first dose of investigational product until end of study</time_frame>
        <population>Safety population included all participants who received treatment with MEDI3617.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI3617 SINGLE AGENT TOTAL</title>
            <description>Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
          <group group_id="O2">
            <title>MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL</title>
            <description>Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
          <group group_id="O3">
            <title>MEDI3617 + BEVACIZUMAB Q2W TOTAL</title>
            <description>Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>MEDI3617 + PACLITAXEL TOTAL</title>
            <description>Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL</title>
            <description>Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR)</title>
          <description>Objective response rate defined as the number of participants with confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR was defined as disappearance of all target lesions, any pathological lymph nodes must have reduction in short axis to less than (&lt;) 10 millimeter (the sum may not be “0” if there are target nodes). PR was defined as at least a 30 percent (%) decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.</description>
          <population>Safety population included all participants who received treatment with MEDI3617.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Response (TTR)</title>
        <description>Time to response (TTR) is defined as the time from the study entry to the first documentation of confirmed CR or confirmed PR. CR was defined as disappearance of all target lesions, any pathological lymph nodes must have reduction in short axis to less than (&lt;) 10 millimeter (the sum may not be “0” if there are target nodes). PR was defined as at least a 30 percent (%) decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Analysis was based on responses confirmed at a repeat assessment made at least 4 weeks after the initial response, with the TTR taken as the first time the response was observed, not the confirmation assessment. TTR was evaluated using the Kaplan-Meier method.</description>
        <time_frame>Time from the first dose of investigational product until end of study</time_frame>
        <population>Safety population included all participants who received treatment with MEDI3617.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI3617 SINGLE AGENT TOTAL</title>
            <description>Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
          <group group_id="O2">
            <title>MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL</title>
            <description>Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
          <group group_id="O3">
            <title>MEDI3617 + BEVACIZUMAB Q2W TOTAL</title>
            <description>Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>MEDI3617 + PACLITAXEL TOTAL</title>
            <description>Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL</title>
            <description>Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Response (TTR)</title>
          <description>Time to response (TTR) is defined as the time from the study entry to the first documentation of confirmed CR or confirmed PR. CR was defined as disappearance of all target lesions, any pathological lymph nodes must have reduction in short axis to less than (&lt;) 10 millimeter (the sum may not be “0” if there are target nodes). PR was defined as at least a 30 percent (%) decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Analysis was based on responses confirmed at a repeat assessment made at least 4 weeks after the initial response, with the TTR taken as the first time the response was observed, not the confirmation assessment. TTR was evaluated using the Kaplan-Meier method.</description>
          <population>Safety population included all participants who received treatment with MEDI3617.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="2.6" upper_limit="2.6"/>
                    <measurement group_id="O2" value="1.2" lower_limit="1.2" upper_limit="1.2"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.6" upper_limit="2.3"/>
                    <measurement group_id="O4" value="1.7" lower_limit="1.6" upper_limit="1.7"/>
                    <measurement group_id="O5" value="NA">No objective response was observed in the MEDI3617 + carboplatin/paclitaxel cohorts.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DOR)</title>
        <description>Duration of response is defined as the duration from the first documentation of objective disease response (ie, confirmed CR or confirmed PR) to the first documented disease progression. The duration of response was censored on the date of last tumor assessment documenting absence of disease progression for participants who have no documented progression prior to data cutoff, dropout, or the initiation of alternate anticancer treatment. Duration of response was evaluated for the subgroup of participants with an objective response using the Kaplan-Meier method.</description>
        <time_frame>Time from the first dose of investigational product until end of study</time_frame>
        <population>Safety population included all participants who received treatment with MEDI3617.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI3617 SINGLE AGENT TOTAL</title>
            <description>Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
          <group group_id="O2">
            <title>MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL</title>
            <description>Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
          <group group_id="O3">
            <title>MEDI3617 + BEVACIZUMAB Q2W TOTAL</title>
            <description>Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>MEDI3617 + PACLITAXEL TOTAL</title>
            <description>Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL</title>
            <description>Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DOR)</title>
          <description>Duration of response is defined as the duration from the first documentation of objective disease response (ie, confirmed CR or confirmed PR) to the first documented disease progression. The duration of response was censored on the date of last tumor assessment documenting absence of disease progression for participants who have no documented progression prior to data cutoff, dropout, or the initiation of alternate anticancer treatment. Duration of response was evaluated for the subgroup of participants with an objective response using the Kaplan-Meier method.</description>
          <population>Safety population included all participants who received treatment with MEDI3617.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" lower_limit="3.7" upper_limit="3.7"/>
                    <measurement group_id="O2" value="NA" lower_limit="17.8" upper_limit="17.8">Due to the lack of available data caused by censoring subjects in the MEDI3617 + bevacizumab Q3W escalation cohorts for this endpoint, median duration of response was not calculable.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="2.9" upper_limit="3.7">Due to the lack of available data caused by censoring subjects in the MEDI3617 + bevacizumab Q2W cohorts for this endpoint, median duration of response was not calculable.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="1.6" upper_limit="17.7">Due to the lack of available data caused by censoring subjects in the MEDI3617 + paclitaxel cohorts for this endpoint, median duration of response was not calculable.</measurement>
                    <measurement group_id="O5" value="NA">No objective response was observed in the MEDI3617 + carboplatin/paclitaxel cohorts.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression (TTP)</title>
        <description>Time to progression (TTP) is defined as time from the start of treatment with MEDI3617 until the documentation of disease progression. The TTP was censored on the date of last tumor assessment documenting absence of tumor progression for participants who have no documented progression prior to data cutoff, dropout, or the initiation of alternate anticancer treatment. Participants having no tumor assessments after the start of treatment with MEDI3617 had TTP censored on the first date of treatment with MEDI3617. TTP was evaluated using the Kaplan-Meier method.</description>
        <time_frame>Time from the first dose of investigational product until end of study</time_frame>
        <population>Safety population included all participants who received treatment with MEDI3617.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI3617 SINGLE AGENT TOTAL</title>
            <description>Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
          <group group_id="O2">
            <title>MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL</title>
            <description>Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
          <group group_id="O3">
            <title>MEDI3617 + BEVACIZUMAB Q2W TOTAL</title>
            <description>Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>MEDI3617 + PACLITAXEL TOTAL</title>
            <description>Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL</title>
            <description>Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression (TTP)</title>
          <description>Time to progression (TTP) is defined as time from the start of treatment with MEDI3617 until the documentation of disease progression. The TTP was censored on the date of last tumor assessment documenting absence of tumor progression for participants who have no documented progression prior to data cutoff, dropout, or the initiation of alternate anticancer treatment. Participants having no tumor assessments after the start of treatment with MEDI3617 had TTP censored on the first date of treatment with MEDI3617. TTP was evaluated using the Kaplan-Meier method.</description>
          <population>Safety population included all participants who received treatment with MEDI3617.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.0" upper_limit="8.6"/>
                    <measurement group_id="O2" value="11.4" lower_limit="0.0" upper_limit="39.4"/>
                    <measurement group_id="O3" value="1.8" lower_limit="0.0" upper_limit="5.3"/>
                    <measurement group_id="O4" value="3.5" lower_limit="0.0" upper_limit="19.4"/>
                    <measurement group_id="O5" value="NA" lower_limit="0.0" upper_limit="4.0">Due to the lack of available data caused by censoring subjects in the MEDI3617 + carboplatin/paclitaxel cohorts for this endpoint, median time to progression was not calculable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-Free Survival (PFS)</title>
        <description>PFS was measured from the start of treatment with MEDI3617 until the documentation of disease progression or death due to any cause, whichever occurred first. PFS was censored on the date of last tumor assessment documenting absence of tumor progression for participants who have no documented progression and were still alive prior to data cutoff, dropout, or the initiation of alternate anticancer treatment. Participants having no tumor assessments after the start of treatment with MEDI3617 had PFS censored on the first date of treatment with MEDI3617. PFS was evaluated using the Kaplan-Meier method.</description>
        <time_frame>Time from the first dose of investigational product until end of study</time_frame>
        <population>Safety population included all participants who received treatment with MEDI3617.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI3617 SINGLE AGENT TOTAL</title>
            <description>Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
          <group group_id="O2">
            <title>MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL</title>
            <description>Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
          <group group_id="O3">
            <title>MEDI3617 + BEVACIZUMAB Q2W TOTAL</title>
            <description>Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>MEDI3617 + PACLITAXEL TOTAL</title>
            <description>Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL</title>
            <description>Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival (PFS)</title>
          <description>PFS was measured from the start of treatment with MEDI3617 until the documentation of disease progression or death due to any cause, whichever occurred first. PFS was censored on the date of last tumor assessment documenting absence of tumor progression for participants who have no documented progression and were still alive prior to data cutoff, dropout, or the initiation of alternate anticancer treatment. Participants having no tumor assessments after the start of treatment with MEDI3617 had PFS censored on the first date of treatment with MEDI3617. PFS was evaluated using the Kaplan-Meier method.</description>
          <population>Safety population included all participants who received treatment with MEDI3617.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.0" upper_limit="8.6"/>
                    <measurement group_id="O2" value="11.4" lower_limit="0.0" upper_limit="39.4"/>
                    <measurement group_id="O3" value="1.7" lower_limit="0.0" upper_limit="5.3"/>
                    <measurement group_id="O4" value="3.5" lower_limit="0.0" upper_limit="19.4"/>
                    <measurement group_id="O5" value="NA" lower_limit="0.0" upper_limit="4.0">Due to the lack of available data caused by censoring subjects in the MEDI3617 + carboplatin/paclitaxel cohorts for this endpoint, median progression-free survival was not calculable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>Overall survival is defined as the time from the start of treatment with MEDI3617 until death. For the participants who were alive at the end of study or lost to follow-up, overall survival was censored on the last date when participants were known to be alive. Overall survival was evaluated using the Kaplan-Meier method.</description>
        <time_frame>Time from the first dose of investigational product until death due to any cause</time_frame>
        <population>Safety population included all participants who received treatment with MEDI3617.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI3617 SINGLE AGENT TOTAL</title>
            <description>Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
          <group group_id="O2">
            <title>MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL</title>
            <description>Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
          <group group_id="O3">
            <title>MEDI3617 + BEVACIZUMAB Q2W TOTAL</title>
            <description>Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>MEDI3617 + PACLITAXEL TOTAL</title>
            <description>Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL</title>
            <description>Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Overall survival is defined as the time from the start of treatment with MEDI3617 until death. For the participants who were alive at the end of study or lost to follow-up, overall survival was censored on the last date when participants were known to be alive. Overall survival was evaluated using the Kaplan-Meier method.</description>
          <population>Safety population included all participants who received treatment with MEDI3617.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" lower_limit="0.3" upper_limit="46.8"/>
                    <measurement group_id="O2" value="25.7" lower_limit="1.3" upper_limit="42.8"/>
                    <measurement group_id="O3" value="7.4" lower_limit="0.5" upper_limit="33.4"/>
                    <measurement group_id="O4" value="14.2" lower_limit="1.0" upper_limit="35.7"/>
                    <measurement group_id="O5" value="NA" lower_limit="1.9" upper_limit="34.4">Due to the lack of available data caused by censoring subjects in the MEDI3617 + carboplatin/paclitaxel cohorts for this endpoint, median overall survival was not calculable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Circulating Levels of Angiopoietin 2 (Ang2)</title>
        <description>Profile of Ang2 post MEDI3617 administration in relation to time course of antibody concentrations.</description>
        <time_frame>Prior to infusion on Cycle 4 and Cycle 5</time_frame>
        <population>All participants who received treatment with MEDI3617 and for whom PD blood samples were collected and evaluated.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI3617 SINGLE AGENT TOTAL</title>
            <description>Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
          <group group_id="O2">
            <title>MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL</title>
            <description>Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
          <group group_id="O3">
            <title>MEDI3617 + BEVACIZUMAB Q2W TOTAL</title>
            <description>Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>MEDI3617 + PACLITAXEL TOTAL</title>
            <description>Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL</title>
            <description>Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Circulating Levels of Angiopoietin 2 (Ang2)</title>
          <description>Profile of Ang2 post MEDI3617 administration in relation to time course of antibody concentrations.</description>
          <population>All participants who received treatment with MEDI3617 and for whom PD blood samples were collected and evaluated.</population>
          <units>nanogram per millileter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 4: Cohort -2 (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.07">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O2" value="NA">Cohort -2 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort -2 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort -2 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort -2 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5: Cohort -2 (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.28">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O2" value="NA">Cohort -2 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort -2 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort -2 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort -2 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4: Cohort -1 (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.11">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O2" value="NA">Cohort -1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort -1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort -1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort -1 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4: Cohort 1 (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.69" spread="4.02"/>
                    <measurement group_id="O2" value="NA">Cohort 1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort 1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort 1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort 1 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5: Cohort 1 (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.22">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O2" value="NA">Cohort 1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort 1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort 1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort 1 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4: Cohort 2 (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="307.53">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O2" value="NA">Cohort 2 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort 2 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort 2 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort 2 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5: Cohort 2 (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="924.66">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O2" value="NA">Cohort 2 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort 2 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort 2 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort 2 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4: Cohort 3 (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="341.21">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O2" value="NA">Cohort 3 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort 3 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort 3 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort 3 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5: Cohort 3 (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="265.86">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O2" value="NA">Cohort 3 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort 3 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort 3 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort 3 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4: Cohort 4 (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="288.10">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O2" value="NA">Cohort 4 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort 4 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort 4 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort 4 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4: Cohort 5 (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1181.14">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O2" value="NA">Cohort 5 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort 5 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort 5 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort 5 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5: Cohort 5 (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1451.43">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O2" value="NA">Cohort 5 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort 5 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort 5 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort 5 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4: Cohort OCE -1 (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="312.27" spread="151.19"/>
                    <measurement group_id="O2" value="NA">Cohort OCE -1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort OCE -1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort OCE -1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort OCE -1 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5: Cohort OCE -1 (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206.43" spread="83.74"/>
                    <measurement group_id="O2" value="NA">Cohort OCE -1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort OCE -1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort OCE -1 was part of the MEDI3617 Single agent total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort OCE -1 was part of the MEDI3617 Single agent total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4: Cohort MB 1A (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O2" value="386.13">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O3" value="NA">Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5: Cohort MB 1A (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O2" value="421.74">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O3" value="NA">Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4: Cohort MB 2A (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O2" value="215.71" spread="143.16"/>
                    <measurement group_id="O3" value="NA">Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5: Cohort MB 2A (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O2" value="228.92">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O3" value="NA">Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4: Cohort MB 3A (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O2" value="218.48">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O3" value="NA">Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5: Cohort MB 3A (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O2" value="247.51">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O3" value="NA">Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4: Cohort MB 4A (n=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O2" value="368.08" spread="257.59"/>
                    <measurement group_id="O3" value="NA">Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5: Cohort MB 4A (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O2" value="353.73">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O3" value="NA">Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4: Cohort MB 1B (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O3" value="466.27">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O4" value="NA">Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5: Cohort MB 1B (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O3" value="750.61">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O4" value="NA">Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4: Cohort MB 2B (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O3" value="421.03">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O4" value="NA">Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5: Cohort MB 2B (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O3" value="387.45">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O4" value="NA">Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4:Cohort MB 3B (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O3" value="141.93">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O4" value="NA">Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4: Cohort MB 4B (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O3" value="229.19" spread="109.02"/>
                    <measurement group_id="O4" value="NA">Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5: Cohort MB 4B (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O3" value="174.65">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O4" value="NA">Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                    <measurement group_id="O5" value="NA">Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4: Cohort MP1 (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MP1 was part of the MEDI3617 + Paclitaxel group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MP1 was part of the MEDI3617 + Paclitaxel group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort MP1 was part of the MEDI3617 + Paclitaxel group.</measurement>
                    <measurement group_id="O4" value="339.35">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O5" value="NA">Cohort MP1 was part of the MEDI3617 + Paclitaxel group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4: Cohort MP2 (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MP2 was part of the MEDI3617 + Paclitaxel group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MP2 was part of the MEDI3617 + Paclitaxel group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort MP2 was part of the MEDI3617 + Paclitaxel group.</measurement>
                    <measurement group_id="O4" value="210.43">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O5" value="NA">Cohort MP2 was part of the MEDI3617 + Paclitaxel group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5: Cohort MP2 (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MP2 was part of the MEDI3617 + Paclitaxel group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MP2 was part of the MEDI3617 + Paclitaxel group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort MP2 was part of the MEDI3617 + Paclitaxel group.</measurement>
                    <measurement group_id="O4" value="166.73">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                    <measurement group_id="O5" value="NA">Cohort MP2 was part of the MEDI3617 + Paclitaxel group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4: Cohort MCP1 (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O5" value="348.53">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5: Cohort MCP1 (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O2" value="NA">Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O3" value="NA">Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O4" value="NA">Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.</measurement>
                    <measurement group_id="O5" value="336.31">Standard deviation was not calculated due to limited sample size (n&lt;3).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Decline in Karnofsky Performance Status (KPS) of ≥ 20 Points at Worst Record On-study Compared With Baseline</title>
        <description>KPS scale: 100 is no evidence of disease; 90 is able to carry on normal activity, minor symptoms of disease; 80 is normal activity with effort, some symptoms of disease; 70 is cares for self; unable to do active work; 60 is requires occasional assistance, but is able to care for most of his needs; 50 is requires considerable assistance with frequent medical care; 40 is disabled, requires special care; 30 is severely disabled, hospitalization is indicated although death is not imminent; 20 is very sick, hospitalization necessary, active support treatment necessary; 10 is moribund, fatal processes progressing rapidly, 0 is dead.</description>
        <time_frame>From start of study drug administration up to 30 days after the last dose of MEDI3617</time_frame>
        <population>Safety population included all participants who received treatment with MEDI3617</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI3617 SINGLE AGENT TOTAL</title>
            <description>Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
          <group group_id="O2">
            <title>MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL</title>
            <description>Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
          <group group_id="O3">
            <title>MEDI3617 + BEVACIZUMAB Q2W TOTAL</title>
            <description>Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>MEDI3617 + PACLITAXEL TOTAL</title>
            <description>Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
          </group>
          <group group_id="O5">
            <title>MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL</title>
            <description>Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Decline in Karnofsky Performance Status (KPS) of ≥ 20 Points at Worst Record On-study Compared With Baseline</title>
          <description>KPS scale: 100 is no evidence of disease; 90 is able to carry on normal activity, minor symptoms of disease; 80 is normal activity with effort, some symptoms of disease; 70 is cares for self; unable to do active work; 60 is requires occasional assistance, but is able to care for most of his needs; 50 is requires considerable assistance with frequent medical care; 40 is disabled, requires special care; 30 is severely disabled, hospitalization is indicated although death is not imminent; 20 is very sick, hospitalization necessary, active support treatment necessary; 10 is moribund, fatal processes progressing rapidly, 0 is dead.</description>
          <population>Safety population included all participants who received treatment with MEDI3617</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From start of study drug administration up to 90 days after the last dose of MEDI3617</time_frame>
      <group_list>
        <group group_id="E1">
          <title>MEDI3617 SINGLE AGENT TOTAL</title>
          <description>Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
        </group>
        <group group_id="E2">
          <title>MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL</title>
          <description>Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.</description>
        </group>
        <group group_id="E3">
          <title>MEDI3617 + BEVACIZUMAB Q2W TOTAL</title>
          <description>Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
        </group>
        <group group_id="E4">
          <title>MEDI3617 + PACLITAXEL TOTAL</title>
          <description>Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.</description>
        </group>
        <group group_id="E5">
          <title>MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL</title>
          <description>Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Faecal incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Medical device pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Glioblastoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Posterior reversible encephalopathy syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Female genital tract fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Chylothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="42"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="16"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="42"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="42"/>
                <counts group_id="E2" events="14" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E3" events="13" subjects_affected="11" subjects_at_risk="38"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="42"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="26" subjects_affected="18" subjects_at_risk="42"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="16"/>
                <counts group_id="E3" events="13" subjects_affected="12" subjects_at_risk="38"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E5" events="5" subjects_affected="3" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="42"/>
                <counts group_id="E2" events="12" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="16" subjects_affected="7" subjects_at_risk="38"/>
                <counts group_id="E4" events="7" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="42"/>
                <counts group_id="E2" events="15" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="42"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="6" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="42"/>
                <counts group_id="E2" events="9" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="42"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" events="6" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="14" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="42"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="42"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="42"/>
                <counts group_id="E2" events="24" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E3" events="16" subjects_affected="13" subjects_at_risk="38"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E5" events="5" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>“MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome” in the agreement description.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mohammed Dar, MD</name_or_title>
      <organization>MedImmune, LLC</organization>
      <phone>301-398-0000</phone>
      <email>information.center@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

